Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06808282 · ClinicalTrials.gov registry record · NA
Effects of Dark Chocolate on the Risk Factors of Cardiovascular Diseases
A NA study of Cardiovascular Diseases, sponsored by San Diego State University.
- Active
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06808282: Active NA study of Cardiovascular Diseases, sponsored by San Diego State University.
NCT06808282 is a NA study of Cardiovascular Diseases that is active but no longer recruiting, run by San Diego State University. The registered enrollment target is 45 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06808282, a NA study of Cardiovascular Diseases, is active but no longer recruiting, sponsored by San Diego State University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Cardiovascular disease (CVD) is the number one cause of death in the US. Epidemiologic evidence supports that antioxidant-rich diets promote health and attenuate or delay the onset of CVD. Cocoa and chocolate products have among the highest antioxidant concentrations compared to other antioxidant food sources. The objective of this study is to examine the effects of regular dark chocolate, bloomed dark chocolate, and white chocolate on cardiovascular health markers.
Primary Outcome
Change of systolic and diastolic blood pressure will be determined to examine effects of dark chocolate consumption vs white chocolate.
Conditions Studied
Interventions
- OTHER White chocolate
- OTHER Dark chocolate
Study Locations (1)
California
- San Diego State University - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-04-01 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT06808282 still lists
NCT06808282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which White chocolate is the first listed.
NCT06808282 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06808282 about?
NCT06808282 is a clinical study titled "Effects of Dark Chocolate on the Risk Factors of Cardiovascular Diseases". Cardiovascular disease (CVD) is the number one cause of death in the US. Epidemiologic evidence supports that antioxidant-rich diets promote health and attenuate or delay the onset of CVD. Cocoa and chocolate products have among the highest antioxidant concentrations compared to other antioxidant fo...
What is the current status of trial NCT06808282?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2011-04-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06808282 study?
This clinical trial studies the following conditions: Cardiovascular Diseases.
What interventions are being tested in trial NCT06808282?
The interventions under investigation include: White chocolate (OTHER), Dark chocolate (OTHER).
Who is sponsoring clinical trial NCT06808282?
This trial is sponsored by San Diego State University, which has 118 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06808282 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06808282's enrollment target sits among peer trials
45 243rd of 300 higher than 55 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI